Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Sinopharm Group Co Ltd (1099)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
19.62 +0.20    +1.03%
04:08:58 - Closed. Currency in HKD ( Disclaimer )
Type:  Equity
Market:  Hong Kong
ISIN:  CNE100000FN7 
  • Volume: 5,504,995
  • Bid/Ask: 19.62 / 19.64
  • Day's Range: 19.38 - 19.96
Sinopharm Group Co 19.62 +0.20 +1.03%

HK:1099 Financials

 
A brief overview of the HK:1099 financials. This summary provides an overview of the most significant critical numbers from each of its financial reports, including the income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health. Users can select to view data from four periods of either annual or quarterly information, allowing them to track financial performance of Sinopharm Group Co Ltd over time.

Sinopharm Group Co. Ltd. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was CNY 147,265.8 million compared to CNY 145,517.77 million a year ago. Net income was CNY 1,420.14 million compared to CNY 1,590.34 million a year ago.

AnnualQuarterly  
InvestingPro Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

1099 Income Statement

Gross margin TTM 8.05%
Operating margin TTM 3.63%
Net Profit margin TTM 1.48%
Return on Investment TTM 8.57%
 Total Revenue  Net Income
Period Ending: Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023
Total Revenue 150649.8 144969.48 155432.51
Gross Profit 13314.84 11926.16 12329.75
Operating Income 7764.89 4720.39 5818.91
Net Income 2957.47 1991.85 2514.1

1099 Balance Sheet

Quick Ratio MRQ 1.05
Current Ratio MRQ 1.36
LT Debt to Equity MRQ 18.78%
Total Debt to Equity MRQ 106.43%
 Total Assets  Total Liabilities
Period Ending: Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023
Total Assets 413065.63 383394.84 419946.62 417691.5
Total Liabilities 263076.1 304013.11 304580.9
Total Equity 120318.74 115933.52 113110.6

1099 Cash Flow Statement

Cash Flow/Share TTM 3.33
Revenue/Share TTM 191.73
Operating Cash Flow  -
 Cash  Net Change in Cash
Period Ending: Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities 56843.25 3656.21 -2632.98
Cash From Investing Activities -957.39 -1167.63 764.46
Cash From Financing Activities -25330.65 -3609.31 185.36
Net Change in Cash 30548.35 -1116.94 -1672.59
* In Millions of CNY (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

1099 Comments

Write your thoughts about Sinopharm Group Co Ltd
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
JAME Megueni
VRAQ Mar 23, 2022 10:18PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
UBS Lowers SINOPHARM TP to $28, Rated Buy
Reply
1 0
Report
Fabio falec
falec Mar 23, 2022 10:18PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
In the end Sinopharm is the only one ripping higher in this bad period for stocks. Better you refer to your TA, foundamental analysis is not your game.
Reply
0 0
Report
JAME Megueni
VRAQ Mar 21, 2022 11:00PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
*Citi Cuts SINOPHARM TP to $26, Rated Buy
Reply
1 0
Report
JAME Megueni
VRAQ Jan 27, 2022 9:26PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
M Stanley Trims SINOPHARM TP to $20.6, Rated Equalweight
Reply
1 0
Report
JAME Megueni
VRAQ Aug 23, 2021 10:36PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
C Suisse Trims SINOPHARM TP to $26; Rated Outperform
Reply
1 0
Report
JAME Megueni
VRAQ Jul 26, 2021 10:47PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
M Stanley Trims SINOPHARM TP to $30.6, Rated Overweight
Reply
1 0
Report
Syrtis Major
Syrtis Major Jun 01, 2021 12:08AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Hi im trying to buy shares on HK market in saxo. It says that I need to buy 400 shares of sinopharm. is this a saxo condition? thanks
Reply
1 0
Report
Ken Ng
Ken Ng Jun 01, 2021 12:08AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
yes。
Reply
1 0
Report
tysonmasato masato
tysonmasato masato Jun 01, 2021 12:08AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Minimum 400
Reply
1 0
Report
JAME Megueni
VRAQ Jun 01, 2021 12:08AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Not only Saxo, 1 Lot=400 Shares
Reply
1 0
Report
JAME Megueni
VRAQ Apr 26, 2021 11:34PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
M Stanley Raises SINOPHARM TP to $31; Rated *Overweight*
Reply
1 0
Report
Mladen Adamović
Mladen Adamović Mar 22, 2021 9:54AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
I've realized I'm fine with 3.57% dividend on this stock, and i hope it could go not go much more down
Reply
2 0
Report
tysonmasato masato
tysonmasato masato Mar 21, 2021 10:53PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Hold almost 3 month always decline price
Reply
0 0
Report
Salam Mnaseer
Salam Mnaseer Feb 15, 2021 4:40AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Why it's not going above 20.. When the vaccine is approved from different countries?
Reply
0 0
Report
George Klee
George Klee Feb 15, 2021 4:40AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Because Sinopharm HK is just a distributor of Sinopharm China's products, and the deals by those countries who approve to use the vaccine are between government to government level.
Reply
2 0
Report
tysonmasato masato
tysonmasato masato Feb 15, 2021 4:40AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Then better sell
Reply
0 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email